• Carolina Mundim Couto Magalhães, Marina Ribeiro Bartholo, Bernardo Henrique Mendes Correa, FerrariMaria de Lourdes AbreuMLAPostgraduate Program in Sciences Applied to Adult Health, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo H, and FerrariTeresa Cristina AbreuTCAPostgraduate Program in Sciences Applied to Adult Health, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Ho.
• Postgraduate Program in Sciences Applied to Adult Health, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
• Med Clin (Barc). 2024 Nov 7.

IntroductionTumor necrosis factor-alpha inhibitor (anti-TNF-α) agents are essential in treating inflammatory bowel diseases (IBD). Their use, however, may cause dermatoses. This study aims to characterize the dermatoses in IBD patients on anti-TNF-α therapy.MethodsA total of 175 IBD patients, 105 (60%) on anti-TNF-α therapy were consecutively selected in a Brazilian referral center of gastroenterology and were evaluated by a dermatologist, regardless of whether they had dermatological complaints.ResultsThe most prevalent disorders in patients receiving anti-TNF-α were skin infections (52.4%), unspecified alopecia not associated with psoriasiform eruptions (32.4%), seborrheic dermatitis (27.6%), infusion/injection reactions (14.5%), and psoriasiform eruptions (11.4%). The group not on anti-TNF-α treatment also presented a high prevalence of infection, seborrheic dermatitis, and alopecia, but no psoriasiform eruptions. There was a higher prevalence of dermatoses, when considered together, in patients taking anti-TNF-α. The use of these agents was independently associated with presence of dermatoses when grouped.ConclusionThe prevalence of dermatoses, considering together, was higher in the anti-TNF-α group. Infections, alopecia, seborrheic dermatitis, administration reactions, and psoriasiform eruptions were the most frequent dermatoses in patients taking anti-TNF-α.Copyright © 2024 Elsevier España, S.L.U. All rights reserved.

9 keywords...

hide…